Low-Dose Oral Minoxidil (LDOM) for Fphl
Verdict: Published with Warning
Across 6 PubMed studies, the evidence for Low-Dose Oral Minoxidil (LDOM) in Fphl grades Tier B — preliminary evidence. Effective, but with safety or population caveats.
B 🟡 B Preliminary Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.69
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
85%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.69
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials
Finding: Oral and topical minoxidil gave equivalent hair-density gains (SMD 0.02, 95% CI -0.25 to 0.29, P=0.88, I2=0%) and hair diameter (SMD -0.25, P=0.34), but oral roughly doubled hypertrichosis risk (RR 2.01, 95% CI 1.18-3.41, P=0.01).
View on PubMed There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses
Finding: Each +1 mg/day of LDOM was associated at 6 months with greater hair diameter (+1.4 um, p=0.01), total hair density (+47.1 hairs/cm2, p=0.007) and terminal density (+9.1 hairs/cm2, p=0.001), but also more hypertrichosis (+17.9%, p=0.006) and cardiovascular adverse events (+4.8%, p=0.004).
View on PubMed Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data
Finding: Across 14 studies (442 patients) LDOM was well tolerated: hypertrichosis 24%, pedal edema 2%, postural hypotension 1.1%, heart-rate changes 1.3%; both hypertrichosis (P<.001) and pedal edema (P=.009) were dose-dependent, and AGA clinical response was 70-100% across 4 studies.
View on PubMed A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss
Finding: Both arms improved significantly from baseline (density and diameter p<0.001), with no significant difference between 0.25 mg oral and 2% topical minoxidil (density 115 vs 113 hairs/cm2, p=0.674; diameter p=0.077) and only trivial side effects.
View on PubMed Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial
Finding: At 24 weeks total hair density rose +12% (95% CI 8.0-16.1) on oral 1 mg vs +7.2% (95% CI 1.5-12.9) on topical 5%, a nonsignificant difference (P=.09); hypertrichosis was higher with oral (27% vs 4%) as was edema (4% vs 0%).
View on PubMed Low-Dose Oral Minoxidil for Female Pattern Hair Loss: A Unicenter Descriptive Study of 148 Women
Finding: In 148 women on LDOM (mostly 1 mg/day) the authors report clinical improvement or stabilization of FPHL by physician and trichoscopic assessment with good tolerability; this uncontrolled descriptive series has no comparator and reports no formal effect-size statistics.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
BOXED WARNING: 'Minoxidil tablets contain the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated. Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent ta… source↗
L4b EU EFSA
Cautious
Minoxidil and its salts must not be used in cosmetic products because of their antihypertensive activity. Minoxidil absorption after scalp application could lead to systemic effects. [Minoxidil is] a peripheral vasodilatator acting on vascular smooth muscle cells, used as a drug in the management of severe hypertension. [The substance is] cardiotoxic in long term oral studies. source↗
L4c UK NHS
Cautious
Minoxidil foam (Regain) is the only licensed treatment for female and male pattern hair loss. You will start on a 0.625mg dose on alternate days; any further changes to the dose will be discussed in your follow up consultations. While you are receiving minoxidil treatment you should have your pulse and blood pressure monitored regularly by your GP. This treatment is not advised for individuals … source↗
L4d TW TFDA / 衛福部
Cautious
洛寧錠10毫克 LONITEN 10MG 衛署藥輸字 第 007538 號 須由醫師處方使用；目前口服 minoxidil 的適應症還是只有用在高血壓，用在治療落髮還是屬於適應症外用藥。 source↗
L4e WHO
Neutral
Minoxidil belongs to the drug class of direct-acting peripheral vasodilators. It exerts its antihypertensive effect by opening adenosine triphosphate (ATP)-sensitive potassium channels, thereby reducing peripheral resistance and lowering blood pressure. The FDA approved minoxidil in tablet form in 1979 under the brand name Loniten specifically for treatment of high blood pressure. Low-dose oral… source↗
L5a NIH Office of Dietary Supplements
Cautious
LONITEN (minoxidil tablets) is indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. Elongation, thickening, and enhanced pigmentation of fine body hair are seen in about 80% of patients taking LONITEN Tablets. This develops within 3 to 6… source↗
L5b Mayo Clinic
Cautious
The doses used to treat hair loss are so low that using it is generally safe if you're monitored carefully by a qualified and experienced health care provider. You shouldn't use it if you're pregnant or intending to become pregnant because of risks to the fetus. source↗
L5c Cleveland Clinic
Supportive
We start with 2.5 mg pills and have our patients split them to 0.625 or, more commonly, 1.25 milligrams a day. It has really been the best drug we ever had for hair growth. Minoxidil is not a drug that a patient can just go buy and take. It needs monitoring. source↗
L5d Harvard Health
Supportive
Recent studies suggest that taking minoxidil as a pill, which has been used for decades to treat high blood pressure, is safe and effective for treating hair loss. It can be helpful for people who aren't getting enough benefit from topical minoxidil, or those who have scalp irritation from the topical form. Oral minoxidil can cause increased hair growth elsewhere on the body, as well as low blo… source↗
L5e Specialty Society (condition-mapped)
Supportive
Oral minoxidil in doses below those likely to lower blood pressure (low dose oral minoxidil) has increasingly been used off-label to treat a variety of hair loss conditions... For female pattern hair loss (FPHL), doses ranging from 0.25 to 1.25 mg daily are usually used for oral minoxidil. The most frequent adverse effect was hypertrichosis (15.1%), while systemic adverse effects included light… source↗